Exclusive: Bayer nears acquisition of Monsanto - sources
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
A trader works at the post where Monsanto Co. is traded on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., August 25, 2016. REUTERS/Brendan McDermid
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
By Arno Schuetze and Greg Roumeliotis
FRANKFURT/NEW YORK (Reuters) - Chemicals and healthcare group Bayer AG
By accepting Bayer's offer, the largest cash acquisition proposal on record, Monsanto is set to give the German company a shot at grabbing the top spot in the fast-consolidating farm supplies industry, combining its crop science business with Monsanto's strength in seeds. It will also set the stage for the deal to be closely scrutinized by antitrust regulators.
The breakthrough in negotiations, which follows more than four months of talks, came after Bayer further improved on the sweetened offer of $127.50 per share in cash it disclosed last week, the people said.
However, the deal will still value Monsanto at less than $130 per share, which the company was previously hoping to fetch, the people added.
Once St. Louis, Missouri-based Monsanto's board of directors approves the deal on Tuesday, Leverkusen-based Bayer's supervisory board will meet on Wednesday to also authorize the transaction, with an announcement expected before the stock market opens in New York on Wednesday, some of the people said.
It is still possible the board of either company could decide to walk away from the deal at the last minute, the people cautioned.
The sources asked not to be identified because the deliberations are confidential. Bayer and Monsanto declined to comment.
Monsanto's shares ended 0.8 percent lower at $106.10 in New York on Tuesday amid uncertainty over whether any agreed deal will clear antitrust hurdles. The stock later climbed to $108.79 in after-hours trading. Bayer shares ended trading in Frankfurt down 0.3 percent at 93.3 euros.
Bayer said last week talks with Monsanto had advanced and that it was willing to offer $127.50 per share, up from $125 previously, valuing Monsanto at more than $65 billion, including debt.
Sources told Reuters that topping up the price secured Bayer access to more privileged information on Monsanto's business performance and paved the way for more detailed negotiations.
"Given recent updates on the Monsanto approach suggest a final conclusion may be close, we suspect (Bayer) will work hard to try and reach a final conclusion before the Meet Management event, if possible," Jefferies Research analyst Jeffrey Wolford said in a research note before the news, referring to Bayer's presentations day for analysts and investors in Cologne next Tuesday.
Bayer's bid to combine its crop chemicals business, the world's second-largest after Syngenta AG
Syngenta last year fought off unwanted suitor Monsanto, only to later agree to a takeover by ChemChina.
(Additional reporting by Oliver Hirt in Zurich and Patricia Weiss and Ludwig Burger in Frankfurt; editing by Greg Mahlich and Andrew Hay)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pandora (P) Advisers Said to Begin Reaching Out to Possible Suitors Following Approach from Sirius (SIRI) - Bloomberg
- Jefferies Cuts Price Target on ConAgra Brands (CAG) Following LW Spinoff
- Jefferies Raises Price Target on US Physical Therapy (USPH) to $63 Following 12-Clinic Acquisition
Create E-mail Alert Related CategoriesMergers and Acquisitions, Reuters
Related EntitiesJefferies & Co, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!